Batch FM 18 and FM 19 showed 12 h floating but drug release was less Dorsomorphin datasheet the FM 10. Matrix forming gums like Xanthan gum and Guar gum also tried from FM 20 and FM 21 for floating behavior, but they were failed to float because of high densities. The drug release profile of cefdinir floating layer is shown in Fig. 3 and Fig. 4. The release profile from FM 10 in a
controlled manner with no burst release was seen. The release profiles seemed dependent on the initial drug concentration. FM 1, FM 2, FM 15, FM 16, FM20 and FM 21 did not show adequate floating tendency. To analyze the cefdinir release mechanism as well as to select the matrix layer for CBT formulation, in vitro release data were fitted into various release equations and kinetic models like first order, zero order, Higuchi and Korsmeyer and Peppas. FM 10 (Matrix layer) was chosen as the optimized formulation because
it showed more linearity between the cumulative percentage cefdinir released versus time (zero order) and Korsmeyer and Peppas, as indicated by the highest value of the correlation coefficient R2 among all the matrix layer formulations, and best fitted both zero order (R2 = 0.9986) and Korsmeyer buy GSK2118436 and Peppas (R2 = 0.9838) models. Thus, it may be concluded that drug release from cefdinir matrix layer is best explained by the Korsmeyer and Peppas model and zero order. The value of the slope (0.8891) indicates that the drug released by zero order type
as shown in Table 5. CBT showed biphasic release (as shown in Fig. 3 and Fig. 4), in the first phase of the drug release profile depended on the concentration of the drug in the upper layer as an immediate dose, was released in less than 60 min, because of fast releasing components of loading layer. Second phase of release, the data were fitted into various kinetic models. Based on the n (0.8891) value of Korsmeyer and Peppas model, the mechanism of cefdinir floating layer followed zero order. The FTIR of plain drug, CBT and Placebo tablet is depicted in Fig. 5. The characteristic peaks of pattern followed the same trajectory as that of the drug alone with minor difference due to dilution effect. Stability enough studies were carried out at 45 °C and 75% RH for three months (climatic zone IV condition for accelerated testing) to assess their long-term (2 years) stability of CBT formulation. The protocols of stability studies were in compliance with the guidelines in the WHO document14 for stability testing of products intended for the global market. After storage, the formulation was subjected to a drug assay, floating behavior and in vitro dissolution studies. The statistical analysis of the parameter of dissolution data (F 2 = 70.